Australian and New Zealand Clinical Practice Guidelines for the Treatment of Bipolar Disorder

,

doi:10.1080/j.1440-1614.2004.01356.x

Cited by 49 publications

(4 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirteen statements were derived from treatment guidelines and meta-analyses for use as quality indicators in the app review ( Table 2 ; [ 16 - 24 ]). A psychiatrist previously involved in the development of the Australian and New Zealand Clinical Practice Guidelines for the Treatment of Bipolar Disorder [ 22 ] then assessed and adjusted the statements for accuracy and comprehensiveness. Comprehensiveness and quality of information were calculated as a score out of 11 and 13 respectively, indicating how many of the core psychoeducation and guideline-derived statements were covered by the app’s information.…”

Section: Methodsmentioning

confidence: 99%

Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality

Nicholas¹,

Larsen²,

Proudfoot³

et al. 2015

J Med Internet Res

386

318

View full text Add to dashboard Cite

BackgroundWith continued increases in smartphone ownership, researchers and clinicians are investigating the use of this technology to enhance the management of chronic illnesses such as bipolar disorder (BD). Smartphones can be used to deliver interventions and psychoeducation, supplement treatment, and enhance therapeutic reach in BD, as apps are cost-effective, accessible, anonymous, and convenient. While the evidence-based development of BD apps is in its infancy, there has been an explosion of publicly available apps. However, the opportunity for mHealth to assist in the self-management of BD is only feasible if apps are of appropriate quality.ObjectiveOur aim was to identify the types of apps currently available for BD in the Google Play and iOS stores and to assess their features and the quality of their content.MethodsA systematic review framework was applied to the search, screening, and assessment of apps. We searched the Australian Google Play and iOS stores for English-language apps developed for people with BD. The comprehensiveness and quality of information was assessed against core psychoeducation principles and current BD treatment guidelines. Management tools were evaluated with reference to the best-practice resources for the specific area. General app features, and privacy and security were also assessed.ResultsOf the 571 apps identified, 82 were included in the review. Of these, 32 apps provided information and the remaining 50 were management tools including screening and assessment (n=10), symptom monitoring (n=35), community support (n=4), and treatment (n=1). Not even a quarter of apps (18/82, 22%) addressed privacy and security by providing a privacy policy. Overall, apps providing information covered a third (4/11, 36%) of the core psychoeducation principles and even fewer (2/13, 15%) best-practice guidelines. Only a third (10/32, 31%) cited their information source. Neither comprehensiveness of psychoeducation information (r=-.11, P=.80) nor adherence to best-practice guidelines (r=-.02, P=.96) were significantly correlated with average user ratings. Symptom monitoring apps generally failed to monitor critical information such as medication (20/35, 57%) and sleep (18/35, 51%), and the majority of self-assessment apps did not use validated screening measures (6/10, 60%).ConclusionsIn general, the content of currently available apps for BD is not in line with practice guidelines or established self-management principles. Apps also fail to provide important information to help users assess their quality, with most lacking source citation and a privacy policy. Therefore, both consumers and clinicians should exercise caution with app selection. While mHealth offers great opportunities for the development of quality evidence-based mobile interventions, new frameworks for mobile mental health research are needed to ensure the timely availability of evidence-based apps to the public.

show abstract

Section: Methodsmentioning

confidence: 99%

Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality

Nicholas¹,

Larsen²,

Proudfoot³

et al. 2015

J Med Internet Res

386

318

View full text Add to dashboard Cite

show abstract

“…With the change to care in the community, healthcare provision became more reliant on relatives [ 9 ] and put relatives centre stage in government policies internationally (World Psychiatric Association: [ 10 ], Canada: [ 11 ], U.K.: [ 12 – 19 ], USA: [ 20 ], Australia and New Zealand: [ 21 , 22 ]). BD relatives’ input, in particular, was acknowledged in both the UK National Institute for Health and Clinical Excellence (NICE) guideline [ 23 ] and the American Psychological Association (APA) [ 24 ] guidelines for BD.…”

Section: Introductionmentioning

confidence: 99%

A qualitative analysis of relatives’, health professionals’ and service users’ views on the involvement in care of relatives in Bipolar Disorder

2015

View full text Add to dashboard Cite

BackgroundRelatives of people with bipolar disorder report that services do not meet their own needs, despite clinical recommendations for the development of care plans for relatives, provision of information regarding their statutory entitlements, and formal involvement in decision making meetings. Further, there is now conclusive evidence highlighting the benefits of relatives’ involvement in improving outcomes for service users, relatives, and the health system as a whole. This qualitative study explored the views of relatives of people with bipolar disorder, service users and healthcare professionals regarding the barriers and the facilitators to relatives’ involvement in care.MethodsThirty five people were interviewed (12 relatives, 11 service users and 12 healthcare professionals). Audio recordings were transcribed verbatim and common themes in participants’ narratives emerged using framework analysis.ResultsParticipants’ accounts confirmed the existence of opportunities for relatives to be involved. These, however, were limited and not always accessible. There were three factors identified that influenced accessibility namely: pre-existing worldviews, the quality of relationships and of communication between those involved, and specific structural impediments.DiscussionThese themes are understood as intertwined and dependent on one another. People’s thoughts, beliefs, attitudes, cultural identifications and worldviews often underlie the ways by which they communicate and the quality of their relationship. These, however, need to be conceptualised within operational frameworks and policy agendas in health settings that often limit bipolar relatives’ accessibility to opportunities for being more formally involved.ConclusionsInvolving relatives leads to clear benefits for relatives, service users, healthcare professionals, and the health system as a whole. Successful involvement of relatives, however, depends on a complex network of processes and interactions among all those involved and requires strategic planning from policy makers, operational plans and allocation of resources.

show abstract

“…There is only a section on the management of hypomania in the guideline on the treatment of acute mania rather than the management of acute hypomanic state in BP II disorder, both in the initial version[29] and the update version. [30] Other popular clinical guidelines, including the American Psychiatric Association guideline,[31] Australian and New Zealand guideline,[32] National Institute for Health, and Clinical Excellence clinical guideline[33] and the Texas Implementation of Medication Algorithms (known as the Texas Medication Algorithm Project previously)[34] do not include recommendations specific to the treatment of BP II disorder.…”

Section: Management Of Bipolar II Disordermentioning

confidence: 99%

Management of Bipolar II Disorder

Wong

2011

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Bipolar II disorder (BP II) disorder was recognized as a distinct subtype in the DSM-IV classification. DSM-IV criteria for BP II require the presence or history of one or more major depressive episode, plus at least one hypomanic episode, which, by definition, must last for at least 4 days. Various studies found distinct patterns of symptoms and familial inheritance for BP II disorder. BP II is commonly underdiagnosed or misdiagnosed. Making an early and accurate diagnosis of BP II is utmost importance in the management of BP II disorder. The clinician should have this diagnosis in mind when he is facing a patient presenting with mood problems, particularly unipolar depression. Quetiapine and lamotrigine are the only agents with demonstrated efficacy in double-blind RCT. Although the evidence for the use of lithium in long-term therapy is largely based on observational studies, the many years of close follow-up, comparatively larger subject numbers, and ‘harder’ clinically meaningful with bipolar disorder outcomes measures, enhance our confidence in its role in treating BP II. With respect to short-term treatment, there is some limited support for the use of risperidone and olanzepine in hypomania and for fluoxetine, venlafaxine and valproate in treating depression. The current clinical debate over whether one should use antidepressants as monotherapy or in combination with a mood stabilizer when treating BP II depression is not yet settled. There is a need for large, well-designed RCTs to cast more definitive light on how best to manage patients with BP II disorder.

show abstract

Australian and New Zealand Clinical Practice Guidelines for the Treatment of Bipolar Disorder

Cited by 49 publications

References 192 publications

Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality

Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality

A qualitative analysis of relatives’, health professionals’ and service users’ views on the involvement in care of relatives in Bipolar Disorder

Management of Bipolar II Disorder

Contact Info

Product

Resources

About